徳島大学 教育・研究者情報データベース(EDB)

1. (英) Iwamoto Noriko

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. (英) Takanashi Megumi

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. (英) Yokoyama Kotoko

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Yonezawa Atsushi

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. 傳田 将也([徳島大学.大学院医歯薬学研究部.薬学域.先端薬学教育研究プロジェクト]/[徳島大学.大学院医歯薬学研究部.薬学域.薬科学部門.創薬科学系.機能分子合成薬学])

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. (英) Hashimoto Motomu

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. (英) Tanaka Masao

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. (英) Ito Hiromu

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. (英) Matsuura Minoru

   役割	任意
   貢献度	任意
   学籍番号	推奨

10. (英) Yamamoto Shuji

    役割	任意
    貢献度	任意
    学籍番号	推奨

11. (英) Honzawa Yusuke

    役割	任意
    貢献度	任意
    学籍番号	推奨

12. (英) Matsubara Kazuo

    役割	任意
    貢献度	任意
    学籍番号	推奨

13. (英) Shimada Takashi

    役割	任意
    貢献度	任意
    学籍番号	推奨

(英) Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.

(英) Monoclonal antibodies have accelerated the availability of treatment options for many diseases in which the molecular mechanism has been elucidated in detail. Therefore, an assay that can universally analyze antibodies for clinical pharmacokinetics and cross-sectional studies would be indispensable. We have developed a universal antibody bioanalysis with a Fab-selective tryptic reaction, named nano-surface and molecular-orientation limited (nSMOL) proteolysis, that collects the specific antibody signature peptides in biological samples. Using the nSMOL method, we have fully validated the bioanalysis of many antibodies, Fc-fusion proteins, and their biosimilars. Inflammatory immune diseases often require long-term clinical management because of the remission and relapse observed. Accurate antibody monitoring in systemic circulation could contribute to the improvement of clinical outcomes. Because several biopharmaceuticals can be selected as practical treatment options, the assay development that quantitates many antibodies simultaneously would be applicable in many theraprutic monitoring. In this study, we have validated the LC-MS bioanalysis method for seven-mixed antibodies (Infliximab, Adalimumab, Ustekinumab, Golimumab, Eculizumab, Etanercept, and Abatacept) using the nSMOL normal reaction condition and two-mixed antibodies (Tocilizumab and Mepolizumab) using the acidified reduction acceleration condition, as reported in our previous papers. Moreover, this multiplexed assay has been verified using clinical patient samples. The nSMOL approach enables the quantitation of several immunosuppressive antibodies simultaneously in human serum, and nSMOL can potentially be applicable to the drug-drug interaction assays or therapeutic antibody monitoring of several inflammatory immune diseases to optimize administration.

1. (英) Antibodies, Monoclonal
2. 校正(calibration)
3. (英) Chromatography, Liquid
4. (英) Drug Monitoring
5. (英) Humans
6. (英) Immunoglobulin Fab Fragments
7. 炎症(inflammation)
8. ナノ粒子(nanoparticles/->キーワード[ナノ粒子])
9. (英) Proteolysis
10. (英) Tandem Mass Spectrometry

1. (英) PublicationType: Journal Article